subject: Semiannual Reports Of Listed Companies To Disclose Material Drug Companies A Few Happy Tears See [print this page] With the semi-annual report of listed companies to disclose
near the end, the warming trend in the pharmaceutical industry is already present, in this one, raw material is undoubtedly the most concern during the first half of this year a sub-sectors. But even in this market rebound to lead the pharmaceutical industry sub-sector, inter-enterprise performance preached "polarization" situation.
Edge products usher in spring Traditional materials for several drug companies for the first half of this year, market conditions in recent years the best period. Semi-annual report from the disclosure of the North China Pharmaceutical, Lukang Pharmaceutical, Northeast Pharmaceutical point of view, its net profit growth in more than 50%. Among them, the North China Pharmaceutical, compared with a year earlier, to achieve profitability, and anti-inflammatory drugs and vitamins as raw material price increases API warming of the main reasons for its performance. Similarly, anti-infective drug on the North China Pharmaceutical raw materials, Lu largest contribution to the performance of anti-medicine, and the return of Northeast Pharmaceutical VC assets, leaving the market optimistic about its growth in the second half performance.
As penicillin industrial salt from the bottom of the six U.S. dollars / BOU risen to the current 18.5 U.S. dollars / BOU, in the first half, North China Pharmaceutical Corporation and Lu medicine penicillin resistant product sales revenue and product gross margin of 10% have appeared ~ 20% increase. Among them, the North China Pharmaceutical penicillin products reached 31.32 percent gross margin, product gross margin cephalosporins reach 15.11%, semi-synthetic penicillin product gross margin of 23.92%, vitamin products gross profit margin was 22.56%.
Lukang Pharmaceutical in the first half net profit rose 74.67 percent, its main product of penicillin industrial salt increased by 10.92% gross profit margin reached 28.71%. But its semi-synthetic antibiotics are still poor profitability, gross margin of -3.74%.
Market rebound in the bulk drug ingredients, while a small number of species with a high concentration of raw materials soaring drug prices, but also brought to the relevant listed company profits. Among them, the production of vitamin B2 and the production of wide economic medicine Xin Fu medicine vitamin B5, the most spectacular. Guangji Pharmaceutical vitamin B2 as the first half of the price increase of 29.96%, 13.63% volume growth, to bring about an increase of 298.28% of its net profit. The net profit growth of Xin Fu medicine is a staggering 1,325.90%, vitamin B5 a 35.95% increase in gross profit.
In addition, the characteristics of bulk drugs in the first half of this year also maintained a steady growth, and related performance of listed companies have also maintained a relatively balanced growth. Cardiovascular disease and the production of anti-tumor medicine bulk drugs and Huahaiyaoye sea is an example, the former net profit up 40.64%, its anti-tumor API gross profit 59.75%; which net profit rose 7.56%, its Plymouth category gross profit of 52.43% API, but Sartan APIs margin on a declining trend.
Semiannual Reports Of Listed Companies To Disclose Material Drug Companies A Few Happy Tears See
